Albumin News and Research

RSS

Study confirms crizotinib drug reduces testosterone levels

A previous study by the University of Colorado Cancer Center reported the common side effect of low testosterone in men treated with the recently approved lung cancer agent, crizotinib.

17 Apr 2013

New study shows exposure to tobacco smoke could negatively impact adolescent kidney function

Exposure to tobacco smoke could negatively impact adolescent kidney function; this is according to a new study led by a team of researchers at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Children's Center.

9 Apr 2013

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its development of Cynviloq (IG-001) at the annual meeting of the American Association for Cancer Research in Washington, DC (April 6th to 10th).

1 Apr 2013

Resuscitation with colloids not recommended

Resuscitation with colloids does not appear to decrease the risk for death, and may even increase mortality, a comprehensive study of trial data reveals.

8 Mar 2013

Carbamylation contributes to heart disease risk among patients with CKD undergoing dialysis

Kidney failure affects 25 million individuals in the U.S. and many more throughout the world. Loss of kidney function means the majority of these patients must undergo dialysis treatments to remove excess fluids and waste products. Although dialysis therapy coupled with medication has improved the life expectancy for people with kidney failure, for unknown reasons, patients' risk of sudden heart failure and death remains 10 to 20 times greater than average.

7 Mar 2013

Hydroxyethyl starch associated with increased risk of death and acute kidney injury

In an analysis of studies that examined critically ill patients requiring an increase in blood fluid volume, intravenous use of the fluid hydroxyethyl starch was not associated with decreased mortality, according to an article appearing in the February 20 issue of JAMA.

21 Feb 2013

Early PBC prognosis advocated

Biochemical response to ursodeoxycholic acid at 6 months is a better predictor for primary biliary cirrhosis prognosis than the current standard of 1 year, study results suggest.

18 Feb 2013

Tumor necrosis factor receptor 2 involved in renal decline in diabetes

Researchers have found that circulating levels of tumor necrosis factor receptor 2 are independently associated with the development of chronic kidney disease in nonobese Japanese patients with Type 2 diabetes.

8 Feb 2013

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.

23 Jan 2013

Albumin may prove a predictor for pneumonia outcomes

Researchers say that assessing serum albumin levels within 24 hours of admission could be a good prognostic marker of community-acquired pneumonia.

21 Jan 2013

BPA adversely affects kidney function in children

Children with high levels of exposure to bisphenol A are at increased risk for low-grade albuminuria, report researchers.

16 Jan 2013

GE Healthcare submits Optison sNDA to aid in detection of cardiovascular diseases

GE Healthcare today announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility.

16 Jan 2013

Vasculitis and the metabolic syndrome frequently co-exist

The metabolic syndrome is significantly more common in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis than healthy individuals, researchers have found.

3 Dec 2012

Kidney disease measures on mortality, ESRD unaffected by age

Regardless of age, estimated glomerular filtration rate and high albuminuria are linked to death and end-stage renal disease, say US scientists who found a lower relative but higher absolute mortality risk difference at older age.

23 Nov 2012

Combination of Abraxane and gemcitabine improves survival of patients with pancreatic cancer

A new cancer drug combination demonstrated significant improvement in overall survival of late-stage pancreatic cancer patients compared to those receiving standard treatment, according to results of a Phase III clinical trial led by physicians from Scottsdale Healthcare's Virginia G. Cancer Center Clinical Trials, a partnership with the Translational Genomics Research Institute (TGen).

17 Nov 2012

Biliary sludge common in dogs

Biliary sludge occurs in around a third of dogs, most often in senior animals, and with no difference in frequency between males and females, shows analysis of ultrasonography data for more than 1000 animals.

14 Nov 2012

Chronic kidney disease associated with increased risk of death regardless of age

A new study from the Johns Hopkins Bloomberg School of Public Health and the Chronic Kidney Disease Prognosis Consortium found that chronic kidney disease and its complications were associated with a higher risk of death regardless of age.

1 Nov 2012

Recurrence risk can be identified before hepatectomy

Patients who are likely to experience disease recurrence after undergoing hepatectomy for hepatocellular carcinoma can be identified by factors that are available preoperatively, indicate the results of a Hong Kong study.

31 Oct 2012

Stability of the novel recombinant human albumins Albucult® and Recombumin® demonstrated by light scattering techniques

In a recently published article, researchers from Novozymes Biopharma (Nottingham, UK) and Malvern Panalytical (Malvern Panalytical, UK) describe collaborative work using light scattering techniques to demonstrate the short- and long-term stability of the novel recombinant human albumins Albucult® and Recombumin®.

From Malvern Panalytical 25 Oct 2012